“The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models”, J of Skin, vol. 9, no. 6, p. s629, Nov. 2025, doi: 10.25251/xbb5zx93.